ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1695

Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 1944

Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2030

Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1957

Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1970

Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1945

Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1887

Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 2134

Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 2136

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1915

Development of an MRI-based Definition of Knee Osteoarthritis: Data from the Multicenter Osteoarthritis Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2036

Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1954

Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1760

Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1751

Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1847

Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].